NEW YORK – Agendia and AI-based digital pathology firm Paige, said today that they've entered a strategic partnership under which they will codevelop treatment planning tools that integrate Paige's cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint and BluePrint diagnostic tests.
The new combined products are intended to enable faster access to predictive and prognostic information to inform the care and treatment of breast cancer patients.